Incidence of type 2 diabetes in Aboriginal Australians: an 11-year prospective cohort study
© Wang et al; licensee BioMed Central Ltd. 2010
Received: 27 January 2010
Accepted: 17 August 2010
Published: 17 August 2010
Diabetes is an important contributor to the health inequity between Aboriginal and non-Aboriginal Australians. This study aims to estimate incidence rates of diabetes and to assess its associations with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) among Aboriginal participants in a remote community.
Six hundred and eighty six (686) Aboriginal Australians aged 20 to 74 years free from diabetes at baseline were followed for a median of 11 years. During the follow-up period, new diabetes cases were identified through hospital records. Cox proportional hazards models were used to assess relationships of the incidence rates of diabetes with IFG, IGT and body mass index (BMI).
One hundred and twenty four (124) new diabetes cases were diagnosed during the follow up period. Incidence rates increased with increasing age, from 2.2 per 1000 person-years for those younger than 25 years to 39.9 per 1000 person-years for those 45-54 years. By age of 60 years, cumulative incidence rates were 49% for Aboriginal men and 70% for Aboriginal women. The rate ratio for developing diabetes in the presence of either IFG or IGT at baseline was 2.2 (95% CI: 1.5, 3.3), adjusting for age, sex and BMI. Rate ratios for developing diabetes were 2.2 (95% CI: 1.4, 3.5) for people who were overweight and 4.7 (95% CI: 3.0, 7.4) for people who were obese at baseline, with adjustment of age, sex and the presence of IFG/IGT.
Diabetes incidence rates are high in Aboriginal people. The lifetime risk of developing diabetes among Aboriginal men is one in two, and among Aboriginal women is two in three. Baseline IFG, IGT and obesity are important predictors of diabetes.
Diabetes is an important cause of coronary heart disease  and renal failure in Aboriginal people , contributing considerably to the 17 year life expectancy gap between Aboriginal and non-Aboriginal Australians. The prevalence of diabetes in Aboriginal Australians is higher than that in the general Australian population . Most of the available data have been from cross-sectional studies. The incidence of diabetes in Aboriginal people from an 8-year follow-up study has been reported . However, there are no data on age-specific and cumulative incidence, which is important information regarding individuals' risks of developing diabetes during a defined period.
Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have been defined by the World Health Organisation . The American Diabetes Association (ADA) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus has recommended lowering the diagnostic threshold of IFG from 6.1 to 5.6 mmol/L, which supposedly results in a similar prevalence of IFG and IGT and increases the concordance between the two groups with respect to risk definition . However, people with IFG may have a different background risk when compared with those with IGT. Predictive values of IFG and IGT for risk of incident diabetes in Aboriginal people have not been investigated.
In this study we aimed to i) describe incidence rates of diabetes in an Aboriginal cohort with a median of 11 years of follow-up; and ii) examine relations of incident diabetes with the presence of baseline IFG, IGT and body mass index (BMI).
In 1992 a community-wide screening program was initiated in a remote Aboriginal community in Australia's Northern Territory. Participants were offered a baseline examination and testing between 1992 and 1995. Eight hundred and ninety seven (897) adults aged 20 to 74 years (representing over 80% of the adult population in the community) were included in the program. Baseline plasma glucose concentrations were measured in 802 participants: 414 participants had 75 g oral glucose tolerance tests (OGTT); 126 had fasting plasma glucose tests without OGTT; and 262 had random plasma glucose tests only. The remaining 95 participants had no baseline plasma glucose tests and were excluded in this analysis.
Of those 802 participants, 71 had clinically diagnosed diabetes before the baseline examination, and 45 had a new diagnosis of diabetes made at the baseline examination according to World Health Organisation (WHO) 1999 criteria . The remaining 686 participants (321 females and 365 males) free from identifiable diabetes at baseline were followed up to 13 years.
The project was approved by the Behavioural and Social Science Ethical Review Committee of the University of Queensland.
New diabetes cases that occurred during the follow-up period after the baseline examination were identified through reviewing hospital records according to ICD-9 CM code of 250 and ICD-10-AM code of E11, and outpatient clinical records. Only the records related to the first documented diagnosis of diabetes for each individual were used for the analysis. All participants' hospital records were followed up to 30 April 2005. For those who were diagnosed as having diabetes during the follow-up period, their follow-up time was from the time of initial screening visit to the time of having a diagnosis first documented in hospital records. Those who had not reached an endpoint were considered "censored" at the date of 30 April 2005. Participants who had no documented diagnoses of diabetes in hospital records and had died before the end of follow-up were censored at the time of death.
An individual with a baseline fasting plasma glucose concentration of 5.6 - 6.9 mmol/L was considered as having IFG while those with a 2 hour plasma glucose (or random glucose) of 7.8 - 11.0 mmol/L as having IGT. Body weight and height were measured at the baseline examination for calculation of BMI (kg/m2). Other baseline measurements included smoking and drinking status, blood pressure, serum cholesterol and urine albumin creatinine ratio (ACR). Detailed baseline data collection methods have been reported elsewhere .
The data were partitioned into age bands of < 25, 25-34, 35-44, 45-54 and 55+ years. For individuals who fell into more than two age bands during the follow-period, their total follow-up time was subdivided and allocated into corresponding age bands as described by Clayton and Hills . Incidence rates were estimated for each age group using the numbers of newly diagnosed diabetes cases divided by the person-years of follow-up. Cumulative incidence of diabetes was estimated using the Kaplan-Meier product-limit method. Rate ratios and their 95% confidence intervals were estimated using the Cox proportional hazards model adjusting for potential confounding factors. All analyses were performed using Stata 10.0 .
Baseline characteristics of study participants
Female (n = 321)
Male (n = 365)
Age (± SD), years
BMI (± SD), kg/m2
Waist circumference (± SD), cm
Systolic pressure (± SD), mmHg
Diastolic pressure (± SD), mmHg
Total cholesterol (± SD), mmol/L
BMI < 25 kg/m2
25 - 29 kg/m2
≥ 30 kg/m2
Incidence rates (per 1000 person-years) of diabetes in Aboriginal people
Incidence rate (95% CI)
2.6 (0.4, 18.2)
2.0 (0.3, 13.9)
2.2 (0.6, 8.9)
22.1 (14.4, 33.9)
7.2 (4.0, 13.0)
12.9 (9.1, 18.2)
26.4 (17.0, 40.9)
23.0 (15.3, 34.7)
24.5 (18.2, 33.0)
53.2 (35.1, 80.8)
23.6 (11.8, 47.2)
39.9 (27.9, 57.0)
28.2 (15.2, 52.4)
34.5 (16.5, 72.4)
30.5 (19.0, 49.1)
Estimated cumulative incidence rates (%)
Cumulative incidence rate (95% CI)
1.4 (0.2, 9.3)
0.9 (0.1, 6.2)
10.0 (5.5, 17.8)
3.0 (1.1, 7.8)
21.0 (14.4, 30.2)
7.9 (4.5, 13.6)
31.1 (23.2, 40.8)
17.6 (12.2, 25.1)
39.2 (3.07, 49.1)
27.9 (20.6, 37.0)
55.4 (46.1, 65.2)
36.6 (27.7, 47.2)
62.8 (53.2, 72.5)
42.4 (31.7, 55.0)
69.9 (60.1, 79.1)
48.6 (36.3, 62.5)
Incidence rates (per 1000 person years) of diabetes by baseline plasma glucose and BMI levels.
Incidence rate (95% CI)
Baseline normal glucose group
8.6 (6.2, 12.0)
21.2 (14.1, 31.9)
53.2 (36.0, 78.7)
Baseline IFG/IGT group
24.6 (13.6, 44.4)
66.9 (41.0, 109.2)
124.7 (73.8, 210.5)
Adjusted rate ratios for developing diabetes by impaired glucose regulation and BMI levels at baseline
Group at baseline
Normal glucose group
Age, sex, BMI
Normal glucose group
Age, sex, BMI, IGT
Normal glucose group
Age, sex, BMI, IFG
Normal BMI group
Age, sex, IFG, IGT
In this study we found that the incidence of diabetes in Aboriginal people was high, comparable to those in other high risk populations such as Pima Indians  and people in Mauritius . The observed diabetes incidence rate among participating Aboriginal adults was higher than those reported in the general Australian population  and in European [13, 14] and American black and white populations . For example, diabetes incidence rates in Aboriginal women were 4-8 times as high as those in the general Australian women for different age groups, while the corresponding values in Aboriginal men were 2-4 times of their general Australian counterparts .
Given the life expectancy of around 60 years for Australian Aboriginal peoples, the cumulative incidence of diabetes at age of 60 years calculated in this study provides an approximate estimate of lifetime risk of developing diabetes in this population. That is, the lifetime risk of diabetes among these Aboriginal men is one in two, and among these Aboriginal women is two in three. A previous study reported that lifetime risk of diabetes was 33% for males and 39% for females in the US . The high lifetime probability of diabetes among Aboriginal Australians calls for implementation of effective primary prevention strategies at the population level. It also calls for a more sophisticated understanding of the nature of diabetes susceptibility in this population.
Results from several longitudinal studies have shown that the presence of IGT/IFG is a significant predictor of the development of diabetes [11, 17–19]. This study adopted the new American Diabetes Associate threshold for IFG. Studies in other populations have shown that those with new threshold of IFG are at increased risk of diabetes [7, 20]. In our study, IFG and IGT identified distinct groups with 36 participants with IFG only and 58 with IGT only. Their contributions to the prediction of incident diabetes are independent of each other, suggesting that the causes and physiological bases of IFG and IGT may be somewhat different. Raised hepatic glucose output and a defect in early insulin secretion are characteristics of IFG, while peripheral insulin resistance is often characteristic of IGT . The presence of either IFG alone or IGT alone doubled the risk of diabetes compared to the normal glucose group. Even after adjusting for the presence of either IFG or IGT, the other remained to be a significant predictor of diabetes. This supports investigation of both IFG and IGT to capture high risk individuals in Aboriginal populations.
Baseline BMI value is an import predictor of diabetes. Overweight individuals have over twofold risk and obese individuals have over fourfold risk of diabetes relative to those with normal baseline BMI values. This finding is consistent with that from a previous study in Aboriginal populations . BMI has been found to be a significant predictor of diabetes in the US general population  and in other high risk populations such as South African Indians , Pima Indians  and Nauruans .
The dose-response relationship between BMI and risk of diabetes exists regardless the presence of IFG/IGT. This is comparable with the results from a study of American Indians which have shown that BMI is a significant predictor of diabetes in both normal glucose tolerance group and IGT group . We found the association between IFG/IGT and diabetes was independent of obesity status. The IFG/IGT group had a higher risk of diabetes in all normal weight, overweight and obese groups. Our findings stress the importance of reducing obesity and managing IFG and IGT on diabetes prevention. However, it should be pointed out that a considerable proportion of diabetes cases were from those with a normal baseline BMI (< 25 kg/m2) and normoglycemia, suggesting that other factors might have been important for the development of diabetes in this population. We previously reported that albuminuria was an important predictor of diabetes . Hematocrit , inflammatory markers [28–31] and gamma-glutamyltransferase  are some potential useful predictors. Assessing novel risk factors in this population is currently in progress.
Some limitations of this study should be pointed out. First, the diabetes cases were identified through reviews of hospital and outpatient records. Ninety two percent of the participants had at least one occasion of hospitalisations during the follow up period. We could miss some diagnoses when diabetes was not severe enough for hospital care. This may underestimate the true incidence. Second, we relied on routinely documented diagnosis information in hospital records for identification of diabetes cases during follow-ups, and misdiagnosis might occur at routine practice. Furthermore, the true date of diagnosis of diabetes was probably earlier than that documented in hospital records. Third, there was potential for loss to follow-up of participants' hospital care due to out-migration to other communities. In reality, the hospital in our study setting is the only hospital serving the entire region, so that most people who had out-migrated to communities within several hundred kilometres, the usual pattern, would still have their hospital care recorded in the centralised hospital data system. Permanent out-migration is very uncommon. Fourth, because the sample size was relatively small for old age groups in this study, the incidence estimates may not be precise, as reflected in the wide 95% confidence intervals. Fifth, the data were collected in a remote community, it remains to be verified if the findings apply to other Aboriginal groups. Caution should be exercised in generalising the findings to the broader Aboriginal population in Australia. Sixth, cumulative incidence rates were estimated based on incidence data collected over one decade rather than over life time. If incidence rates change over time, so does an individual's life time risk of diabetes. Finally, the presence of IGT among some participants was determined according to the postprandial glucose values due to the absence of oral glucose tolerance tests. Some IGT individuals might have been misclassified as normal.
Diabetes incidence rates are high in Aboriginal people. The lifetime risk of developing diabetes among Aboriginal men is one in two, and among Aboriginal women is two in three. IFG and IGT identify people who have an increased risk of diabetes. Baseline IFG, IGT and obesity are important predictors of diabetes.
We especially thank the Aboriginal people who participated in this study. The baseline data were collected by the renal research team at the Menzies School of Health Research, Darwin, Australia. David Ung at the Northern Territory Department of Health and Community Services assisted in data collection. ZW's work is supported by an NHMRC Research Fellowship (#511013). DS's work is supported by an NHMRC Postdoctoral Fellowship (#569919).
- Wang Z, Hoy WE: Association between diabetes and coronary heart disease in Aboriginal people: are women disadvantaged?. Med J Aust. 2004, 180 (10): 508-511.PubMedGoogle Scholar
- Hoy WE, Mathews JD, McCredie DA, Pugsley DJ, Hayhurst BG, Rees M, Kile E, Walker KA, Wang Z: The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int. 1998, 54 (4): 1296-1304. 10.1046/j.1523-1755.1998.00099.x.View ArticlePubMedGoogle Scholar
- Wang Z, Hoy WE: Hypertension, dyslipidemia, body mass index, diabetes and smoking status in Aboriginal Australians in a remote community. Ethn Dis. 2003, 13 (3): 324-330.PubMedGoogle Scholar
- Daniel M, Rowley KG, McDermott R, Mylvaganam A, O'Dea K: Diabetes incidence in an Australian Aboriginal population. An 8-year follow-up study. Diabetes Care. 1999, 22 (12): 1993-1998. 10.2337/diacare.22.12.1993.View ArticlePubMedGoogle Scholar
- World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications; part 1: diagnosis and classification of diabetes melitus. 1999, Geneva: Department of Noncommunicable disease Surveillance, WHOGoogle Scholar
- Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, et al: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003, 26 (11): 3160-3167. 10.2337/diacare.26.11.3160.View ArticlePubMedGoogle Scholar
- Vaccaro O, Riccardi G: Changing the definition of impaired fasting glucose: impact on the classification of individuals and risk definition. Diabetes Care. 2005, 28 (7): 1786-1788. 10.2337/diacare.28.7.1786.View ArticlePubMedGoogle Scholar
- Clayton D, Hills M: Statistical models in epidemiology. 1993, Oxford: Oxford University PressGoogle Scholar
- StataCorp: Stata Statistical Software: Release 10.0. 2007, College Station. TX: StataCorp LPGoogle Scholar
- Knowler WC, Bennett PH, Hamman RF, Miller M: Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol. 1978, 108 (6): 497-505.PubMedGoogle Scholar
- Soderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, Stenlund H, Gareeboo H, Alberti KG, Shaw J: High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med. 2004, 256 (1): 37-47. 10.1111/j.1365-2796.2004.01336.x.View ArticlePubMedGoogle Scholar
- Barr ELM, Magliano DJ, Zimmet P, Polkinghorne KR, Atkins RC, Dunstan DW, Murray SG, Shaw JE: AusDiab 2005. The Australian Diabetes Obesity and Lifestyle Study. 2006, Melbourne: The International Diabetes InstituteGoogle Scholar
- Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, Meyboom-de Jong B: Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol. 2003, 18 (8): 793-800. 10.1023/A:1025369623365.View ArticlePubMedGoogle Scholar
- Njolstad I, Arnesen E, Lund-Larsen PG: Sex differences in risk factors for clinical diabetes mellitus in a general population: a 12-year follow-up of the Finnmark Study. Am J Epidemiol. 1998, 147 (1): 49-58.View ArticlePubMedGoogle Scholar
- Lipton RB, Liao Y, Cao G, Cooper RS, McGee D: Determinants of incident non-insulin-dependent diabetes mellitus among blacks and whites in a national sample. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1993, 138 (10): 826-839.PubMedGoogle Scholar
- Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF: Lifetime risk for diabetes mellitus in the United States. JAMA. 2003, 290 (14): 1884-1890. 10.1001/jama.290.14.1884.View ArticlePubMedGoogle Scholar
- Lee ET, Welty TK, Cowan LD, Wang W, Rhoades DA, Devereux R, Go O, Fabsitz R, Howard BV: Incidence of diabetes in American Indians of three geographic areas: the Strong Heart Study. Diabetes Care. 2002, 25 (1): 49-54. 10.2337/diacare.25.1.49.View ArticlePubMedGoogle Scholar
- Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG: Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?. Diabetes Care. 1999, 22 (3): 399-402. 10.2337/diacare.22.3.399.View ArticlePubMedGoogle Scholar
- Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M: Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004, 53 (7): 1782-1789. 10.2337/diabetes.53.7.1782.View ArticlePubMedGoogle Scholar
- Tai ES, Goh SY, Lee JJ, Wong MS, Heng D, Hughes K, Chew SK, Cutter J, Chew W, Gu K, et al: Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care. 2004, 27 (7): 1728-1734. 10.2337/diacare.27.7.1728.View ArticlePubMedGoogle Scholar
- Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002, 19 (9): 708-723. 10.1046/j.1464-5491.2002.00835.x.View ArticlePubMedGoogle Scholar
- Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF: Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007, 30 (6): 1562-1566. 10.2337/dc06-2544.View ArticlePubMedGoogle Scholar
- Motala AA, Pirie FJ, Gouws E, Amod A, Omar MA: High incidence of Type 2 diabetes mellitus in South African Indians: a 10-year follow-up study. Diabet Med. 2003, 20 (1): 23-30. 10.1046/j.1464-5491.2003.00782.x.View ArticlePubMedGoogle Scholar
- Knowler WC, Saad MF, Pettitt DJ, Nelson RG, Bennett PH: Determinants of diabetes mellitus in the Pima Indians. Diabetes Care. 1993, 16 (1): 216-227. 10.2337/diacare.16.1.216.View ArticlePubMedGoogle Scholar
- King H, Zimmet P, Raper LR, Balkau B: The natural history of impaired glucose tolerance in the Micronesian population of Nauru: a six-year follow-up study. Diabetologia. 1984, 26 (1): 39-43. 10.1007/BF00252261.View ArticlePubMedGoogle Scholar
- Wang Z, Hoy WE: Albuminuria as a marker of the risk of developing type 2 diabetes in non-diabetic Aboriginal Australians. Int J Epidemiol. 2006, 35: 1331-1335. 10.1093/ije/dyl115.View ArticlePubMedGoogle Scholar
- Tulloch-Reid MK, Hanson RL, Saremi A, Looker HC, Williams DE, Krakoff J, Knowler WC: Hematocrit and the incidence of type 2 diabetes in the pima indians. Diabetes Care. 2004, 27 (9): 2245-2246. 10.2337/diacare.27.9.2245.View ArticlePubMedGoogle Scholar
- Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT: C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004, 47 (8): 1403-1410. 10.1007/s00125-004-1472-x.View ArticlePubMedGoogle Scholar
- Mohan V, Deepa R, Velmurugan K, Premalatha G: Association of C-reactive protein with body fat, diabetes and coronary artery disease in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-6). Diabet Med. 2005, 22 (7): 863-870. 10.1111/j.1464-5491.2005.01541.x.View ArticlePubMedGoogle Scholar
- Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001, 286 (3): 327-334. 10.1001/jama.286.3.327.View ArticlePubMedGoogle Scholar
- Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003, 163 (1): 93-99. 10.1001/archinte.163.1.93.View ArticlePubMedGoogle Scholar
- Nakanishi N, Suzuki K, Tatara K: Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004, 27 (6): 1427-1432. 10.2337/diacare.27.6.1427.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/10/487/prepub